Ginkgo Bioworks Holdings Stock Today
| DNA Stock | USD 7.33 0.15 2.09% |
Performance0 of 100
| Odds Of DistressOver 68
|
Ginkgo Bioworks is trading at 7.33 as of the 12th of October 2024, a 2.09 percent up since the beginning of the trading day. The stock's open price was 7.18. Ginkgo Bioworks has more than 68 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Ginkgo Bioworks Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of September 2024 and ending today, the 12th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of April 2021 | Category Healthcare | Classification Health Care |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Ginkgo Bioworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. The company has 43.1 M outstanding shares of which 8.19 M shares are currently shorted by investors with about 4.48 days to cover. More on Ginkgo Bioworks Holdings
Moving together with Ginkgo Stock
Moving against Ginkgo Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ginkgo Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Doric Nimrod Air One Limited, Dalradian Resources Inc, DNA Oyj, DNA, More Return Public Company Limited, An Giang Power and Water Supply JSC] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGinkgo Bioworks can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ginkgo Bioworks' financial leverage. It provides some insight into what part of Ginkgo Bioworks' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ginkgo Bioworks Holdings (DNA) is traded on New York Stock Exchange in USA. It is located in 27 Drydock Avenue, Boston, MA, United States, 02210 and employs 1,218 people. Ginkgo Bioworks is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 399.03 M. Ginkgo Bioworks Holdings runs under Biotechnology sector within Health Care industry. The entity has 43.1 M outstanding shares of which 8.19 M shares are currently shorted by investors with about 4.48 days to cover.
Ginkgo Bioworks Holdings has about 1.32 B in cash with (295.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84.
Check Ginkgo Bioworks Probability Of Bankruptcy
Ownership AllocationGinkgo Bioworks Holdings has a total of 43.1 Million outstanding shares. Over half of Ginkgo Bioworks' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Ginkgo Ownership Details
Ginkgo Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| D. E. Shaw & Co Lp | 2024-06-30 | 17.4 M | |
| Norges Bank | 2024-06-30 | 15.6 M | |
| Qube Research & Technologies | 2024-06-30 | 15.5 M | |
| Geode Capital Management, Llc | 2024-06-30 | 15.3 M | |
| Aqr Capital Management Llc | 2024-06-30 | 10.4 M | |
| State Street Corp | 2024-06-30 | 10.1 M | |
| Exor Investments (uk) Llp | 2024-03-31 | 10 M | |
| Monaco Asset Management | 2024-06-30 | 9.8 M | |
| Welch & Forbes Llc | 2024-06-30 | 7.3 M | |
| Viking Global Investors Lp | 2024-06-30 | 143.1 M | |
| Vanguard Group Inc | 2024-06-30 | 139 M |
Ginkgo Bioworks Historical Income Statement
Ginkgo Stock Against Markets
Ginkgo Bioworks Corporate Management
| Anna Wagner | Senior Development | Profile | |
| Samantha Sutton | Head People | Profile | |
| Mark Dmytruk | Chief Officer | Profile | |
| Reshma Shetty | President, Founder | Profile | |
| Joshua Dunn | Head Design | Profile | |
| Thomas Knight | Founder | Profile | |
| Austin Che | Head Founder | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ginkgo Bioworks Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.00) | Revenue Per Share 3.692 | Quarterly Revenue Growth (0.30) | Return On Assets (0.22) | Return On Equity (0.77) |
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.